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Laboratory Studies
Role of Vasopressin in Cardiovascular
Response to Central Cholinergic Stimulation
in Rats
Yutaka Imai, Keishi Abe, Shuichi Sasaki, Naoyoshi Minami, Masanori Munakata,
Shigeu Yumita, Toshima Nobunaga, Hiroshi Sekino, and Kaoru Yoshinaga
The cardiovascular effects of centrally administered cholinomimetics were examined in con-
scious Long-Evans and Brattleboro rats. Carbachol (1 ^tg/kg) or physostigmine (50 /ug/kg)
induced a long-lasting increase in blood pressure and a decrease in heart rate in Long-Evans
rats whereas no bradycardia was observed in Brattleboro rats, and the pressor response was
significantly less than that in Long-Evans rats. The cardiovascular responses to nicotine (30 jtg/
kg) in Brattleboro rats were not different from those in Long-Evans rats. Intravenous
vasopressin antagonist, dfCH^jTyrCMe) arginine vasopressin, significantly attenuated the
pressor response and eliminated the bradycardic response to carbachol hi Long-Evans rats.
However, the pressor response to carbachol in Brattleboro rats was still significantly less than
that in Long-Evans rats treated with vasopressin antagonist. Intravenous phentolamine
partially inhibited the pressor response to carbachol in Long-Evans rats and completely
eliminated it in Brattleboro rats. Combined intravenous treatment with phentolamine and
vasopressin antagonist completely eliminated the pressor response to carbachol in Long-Evans
rats. Centrally administered methylatropine eliminated either the hypertensive or bradycardic
response to carbachol in Long-Evans rats. These results indicate that the pressor and
bradycardic response to carbachol or physostigmine is mediated by the central muscarinic
receptor mechanism. Hypertensive response to intracerebroventriculaiiy administered carba-
chol in normal rats is mediated both by an increase in central sympathetic outflow and in
circulating vasopressin. The bradycardia seems to be mediated mainly by vasopressin.
{Hypertension 1989;13:549-557)
It is well known that central cholinergic stimu-lation evokes hypertension and bradycardiain several species of animal and in humans
(see References 1 and 2 for review). The mecha-
nisms responsible for the cardiovascular responses
to central cholinergic stimulation are controver-
sial. Some previous studies have emphasized that
the cardiovascular responses to central choliner-
gic stimulation are mediated by a change in sym-
pathetic outflow from the central nervous system
(CNS).23 There are also reports that cholinergic
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agents act centrally to stimulate vasopressin
release.4-6 Hoffman and Phillips7 and Hoffman8
observed that the hypertensive response to central
cholinergic stimulation is mediated, at least in part,
by the release of vasopressin. It has been reported
that some physiological and pharmacological stim-
uli elevate blood pressure and circulating vasopres-
sin levels simultaneously. However, the role of the
raised vasopressin levels in the pressor response to
such stimuli is uncertain.9-'2 In the present study
we have examined qualitatively and quantitatively
the contribution of circulating vasopressin to the
hypertensive and bradycardic responses to cen-
trally administered cholinomimetics. To do this we
have used a vasopressin antagonist as well as auto-
nomic blockers in normal Long-Evans rats (LE)
and in Brattleboro (DI) rats; endogenous vasopres-
sin is lacking in the latter.13
Materials and Methods
Male rats weighing 250-390 g (22-27 weeks old)
and male homozygous DI rats weighing 200-340 g
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(21-27 weeks old) were used. The lateral cerebro-
ventricle was cannulated under pentobarbital anes-
thesia (Nembutal, Abbott Laboratories, North Chi-
cago, Illinois) by means of PE 20 polyethylene
tubing (Clay Adams, Parsippany, New Jersey). Coor-
dinates for the cannulation with respect to the
bregma were 1.0 mm posterior, 1.5 mm lateral, and
5 mm deep. The cannulae were filled with artificial
cerebrospinal fluid (ACSF) (composition[mmol/l]:
Na 148.4, K 3.0, Mg 1.0, Ca2.5, HPO41.5, Cl 156.9,
and glucose 3.0) and fixed in place with stainless
steel anchoring screws and orthopedic bone cement.
A week after the cerebroventricular cannulation,
the left femoral artery and vein were cannulated by
means of polyethylene tubing (tapered PE-100 tub-
ing and PE-20 tubing, respectively) under ether
anesthesia. The catheters were led subcutaneously
and exteriorized at the nape of the neck. During
surgery, 15 mg aminobenzyl penicillin was admin-
istered. The rats were housed in individual plastic
metabolic cages in a room with constant tempera-
ture (23° C) and humidity that was lit from 8:00 AM
to 8:00 PM daily. The arterial catheters were con-
nected to a hydraulic swivel tethering system. The
rats were allowed to recover for at least 24 hours
after surgery and were conscious and unrestrained
during the studies. Blood pressure was recorded
from the femoral artery catheter with a P23Ib trans-
ducer (Gould-Statham, Oxnard, California) and
strain-gauge amplifier (model 1321, NEC-San-ei,
Tokyo, Japan). Heart rate was counted from the
phasic pressure wave by a cardiotachometer (model
1257, NEC-San-ei). Phasic arterial blood pressure,
mean arterial blood pressure (MBP), and heart rate
were recorded continuously on a recticorder
(Rectigraph-8K, NEC-San-ei). To keep the arterial
catheter patent, heparin saline solution (100 unit/ml)
was continuously infused through the arterial cath-
eter at a rate of 80 /xl/hr. All drugs for intracere-
broventricular and intravenous administration were
dissolved in ACSF or physiological saline (0.9%),
respectively. Injections were given at a volume of
150 fx\ i.v. Drug solution for intracerebroventricular
injection was pumped into a PE-20 tubing that was
connected with microsyringe (Hamilton, Reno,
Nevada) containing ACSF. In the PE-20 tubing,
drug solution was insulated from ACSF by air (0.1-
0.2 p\). A total injection volume of 5 /il i.c.v. was
given; 2 /A! or less ACSF was contained in the dead
space of the intracerebroventricular cannula fol-
lowed by 3 pi or less of drug solution, which was
pushed by ACSF of the injection system (PE-20
tubing and microsyringe). Drug solutions were
delivered over a period of 5 seconds. The drugs
used in the present study were: carbachol (K&K
Laboratories, Plainview, New York), physostig-
mine (Nakarai Chemicals, Tokyo, Japan), nicotine
hydrogen tartrate salt (Sigma Chemical Co., St.
Louis, Missouri), phentolamine mecylate (CIBA-
GEIGY, Summit, New Jersey), methylatropine
bromide (Takeda, Tokyo, Japan), propranolol-
HC1 (ICI, London, UK), phenylephrine-HCl (Sigma
Chemical Co.), l-Q3-mercapto-/3, cyclopentameth-
ylene propionic acid), 2-(O-methyl) tyrosine argi-
nine vasopressin [d(CH2)5Tyr(Me)]AVP; vasopres-
sin antagonist, Peninsula, San Carlos, California,
and l-(3-mercaptopropionic acid)-8-O-arginine
vasopressin (DDAVP, Ferring, Malmo, Sweden).
Post mortem examination of the brain was per-
formed to verify the position of the intracerebro-
ventricular cannulas.
Experimental Protocol
Experiments were carried out as described below.
Cardiovascular effects of intravenous and intra-
cerebroventricular cholinomimetics in Long-Evans
and Brattleboro rats. The dose-response relation
for the cardiovascular response to carbachol (0.1,
0.3, and 1.0 Mg/kg i.c.v.; in eight LE and eight DI
rats) was examined. Thirty minutes were allowed
for recovery after the 0.1 /ig/kg dose and 1 hour
after the 0.3 /ig/kg dose. The time courses of the
response to carbachol (1 /ig/kg i.c.v.; 11 LE and 22
DI rats), carbachol (3 ^.g/kg i.v.; seven LE and
seven DI rats), and physostigmine (50 /tg/kg i.c.v.;
six LE and six DI rats) were examined. In five LE
rats the reproducibility of the cardiovascular
response to carbachol (1 /Ag/kg i.c.v.) was exam-
ined, allowing intervals of 2 hours and 24 hours.
The cardiovascular responses to nicotine (30 fig/
kg i.c.v.) were examined in seven LE and DI rats.
Modification of the cardiovascular effect of intra-
cerebroventricular carbachol in Long-Evans rats by
vasopressin analogues. In the experiment described
below, carbachol in a dose of 1 /xg/kg i.c.v. was
used to produce a "standard" cardiovascular
response to carbachol.
The cardiovascular effects of intracerebroventric-
ular carbachol before and during treatment with a
vasopressin-specific vascular receptor antagonist
(VPVRA), d(CH2)3Tyr(Me)AVP, were examined in
five LE rats. Two hours after the control experi-
ment, the vasopressin antagonist was administered
in a bolus dose of 1 fig/kg i.v. followed by an
infusion of 5 /ig/kg/hr for 1 hour. The cardiovascu-
lar effect of intracerebroventricular carbachol was
reexamined during the infusion of the antagonist.
The control response to the vasopressin antagonist
given alone (i.v.) was also obtained. To determine
the degree of vasopressin blockade by the antago-
nist, the pressor effect of vasopressin (100 ng/kg
i.v.) was examined before and during infusion of the
antagonist in five LE rats.
The cardiovascular effects of intracerebroventric-
ular carbachol before and during treatment with
DDAVP, a vasopressin antidiuretic agonist, were
examined in five DI rats. After the control experi-
ment, DDAVP was infused at a rate of 0.2 ng/
kg/min for 24 hours. The cardiovascular effect of
intracerebroventricular carbachol was reexamined
during the infusion of DDAVP. To determine the
antidiuretic effect of DDAVP, 24-hour urinary pro-
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FIGURE 1. Line graphs of effects of car-
bachol (I fig/kg i.c.v.) on mean arterial
pressure (MAP) and heart rate (HR) in
Long-Evans (LE) and Brattleboro (DI) rats.
In some DI rats a slight decrease in blood
pressure was observed after hypertension.
Modification of the effects of carbachol
(1 fig/kg i.c.v.) on MAP and HR by a
vasopressin-specific vascular receptor
antagonist(VPVRA), d(CH2),Tyr(Me)AVP,
in LE rats is also illustrated in the figure.
0 1 2 3 4 10 20 30(min)
duction preceding the control experiments was com-
pared with that during DDAVP infusion.
Modification of cardiovascular effect of intrace-
rebroventricular carbachol by autonomic blockade.
The cardiovascular effect of intracerebroventricular
carbachol was examined before and after adminis-
tration of phentolamine (3 mg/kg i.v. in six LE rats
and five DI rats), methylatropine (1 mg/kg i.v. in
five LE rats or 3 /ig/kg i.c.v. in five LE rats), or
propranolol (2 mg/kg i.v. in five LE rats). Two
hours after the control experiment, autonomic block-
ers were administered. Five minutes after intracere-
broventricular or 15 minutes after intravenous treat-
ment with the autonomic blocker, carbachol was
administered intracerebroventricularly. Twenty-
four hours before or after the experiment, the
control response to the appropriate blocker alone
was examined together with the degree of auto-
nomic blockade. In five LE rats the cardiovascular
response to intracerebroventricular carbachol was
examined before and 15 minutes after combined
treatment with the vasopressin antagonist (5 /ig/kg
i.v.) and phentolamine (3 mg/kg i.v.). Twenty-four
hours later, the control response of combined treat-
ment with the two antagonists was examined.
Statistical Method
All values reported are the mean±SEM, unless
otherwise stated. Dose-response curves and the time
course of change in cardiovascular parameters were
compared by means of two-way analysis of variance
(ANOVA) for the repeated measurements. In com-
paring the three time courses, a two-way ANOVA
that included all three groups was performed first.
Comparison between any two groups was done by the
Bonferroni correction for multiple comparison. One-
way ANOVA and Student's t test were applied as the
statistical methods to other results.
Results
In some of the experiments, some rats were used
twice for different experimental protocols, allowing
a recovery interval of 24 hours between experi-
ments. In five DI rats used twice for different
experimental protocols, 24-hour urinary volume
after the experiment (315±25 ml/24 hr) was not
different from that preceding the experiment (326± 17
ml/24 hrs). Body weight fell slightly but significantly
24 hours after the experiment (295±5 vs. 287±4 g,
n=5 LE rats); 273±3 vs. 268±4 g (n=5 DI rats).
Cardiovascular Effect of Carbachol
Figure 1 shows the cardiovascular response to
carbachol, 1 fig/kg i.c.v., in LE and DI rats.
Intracerebroventricular carbachol induced a long
lasting increase in blood pressure in both strains. In
some DI rats, a slight decrease in blood pressure
was observed after the hypertension. As shown in
the figure, the hypertensive response to intracere-
broventricular carbachol in DI rats was significantly
less than that in LE rats throughout the period of
the response (FUIO=231.5, p<0.001). Intracerebro-
ventricular carbachol elicited an initial transient
tachycardia followed by prolonged bradycardia in
the LE rats, whereas in the DI rats only tachycardia
was observed (F, j,0=39.4, p<0.001). The maximum
changes in blood pressure and heart rate were used
to construct dose-response curves (Figure 2). Intra-
cerebroventricular carbachol caused dose-dependent
increases in blood pressure and decreases in heart
rate in LE rats, whereas in DI rats the responses
were not dose dependent. Overall, the hypertensive
and bradycardic responses to intracerebroventric-
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FIGURE 2. /Vote of dose-response curves for changes in
mean arterial pressure (AA/AP) and heart rate (AHR) to
intracerebroventricular carbachol. Open symbols, Long-
Evans rats; closed symbols, Brattleboro rats.
ular carbachol in the LE rats were significantly
greater than those in the DI rats (FlM=65.3, /?<0.001
in blood pressure; FtM=23.9, /?<0.001 in heart
rate).
Carbachol (3 /^g/kg i.v.) induced a short-lasting
and steep decrease in blood pressure that returned
to the initial level within 1 minute in both strains.
The magnitude of the accompanying tachycardia
was not significantly different between the two
strains, although it was more persistent in the DI
rats (Figure 3; F196=5.0, p<0.03).
Reproducibility of the cardiovascular response to
intracerebroventricular carbachol was examined,
allowing 2-hour and 24-hour intervals, and was
excellent (Figure 4) (blood pressure for 24 hours:
F,
-go=0.66, for 2 hours: F1SO=0.92; heart rate for 24
hours: F)i!O=0.42, for 2 hours: FITSO=0.23).
Cardiovascular Effect of Physostigmine
The cardiovascular response to intracerebro-
ventricular physostigmine was essentially the same
as observed in intracerebroventricular carbachol.
Pressor responses to intracerebroventricular phy-
sostigmine in DI rats (19±2 mm Hg, 6 minutes
after injection) was significantly less than that in
LE rats (36±4 mm Hg, 6 minutes after injection,
F|ioo= 136.3, p<0.001). Intracerebroventricular
physostigmine induced a transient tachycardia
(57±17 beats/min, 3 minutes after injection) fol-
lowed by a long-lasting bradycardia in the LE rats
(-38±17 beats/min, 10 minutes after injection),
whereas bradycardia was scarcely observed in the
DI rats (43±18 beats/min, 3 minutes after injection
and 13±15 beats/min, 10 minutes after injection)
(tachycardiac phase, 0-6 minutes, F,
 w=0.2; brady-
cardic phase, 6-20 minutes, F1>70=12.8, p<0.00l).
Cardiovascular Effect of Nicotine
Intracerebroventricular nicotine induced an initial,
transient rise in blood pressure and heart rate (LE,
16±3 mm Hg and 35± 11 beats/min; DI, 20± 11 mm Hg
and 37 ± 16 beats/min) followed by a decrease in blood
pressure (LE, -7±1 mm Hg; DI, -6±3 mm Hg)
accompanied by bradycardia (LE, -41 ±8 beats/min;
DI, -23±11 beats/min). The hypertensive and brady-
cardic responses to intracerebroventricular nicotine in
the two strains were not different (p>0.\).
Modification of Cardiovascular Effect of
Carbachol by Vasopressin-Antagonist
Vasopressin antagonist (VPVRA) alone did not
cause any changes in blood pressure and heart rate
in LE rats. As shown in Figure 1, the three time
courses of change in blood pressure, that is, the
responses to intracerebroventricular carbachol in
LE rats, in DI rats, or in LE rats during vasopressin
antagonist, were significantly different (F2jo8=6.94,
p<0.001). The Bonferroni correction for multiple
comparison revealed that the responses between
any two groups were significantly different (p<0.05),
i.v. Carbachol
OLE rats
• DI rats
FIGURE 3. Line graphs of effects of car-
bachol (3 ng/kg i.v.) on mean arterial
pressure (MAP) and heart rate (HR) in
Long-Evans (LE) and Brattleboro (DI) rats.
0 1 2 10 20 30(min)
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FIGURE 4. Line graphs demonstrating
reproducibility of the cardiovascular
responses to carbachol (1 ftg/kg i.c.v.)
allowing intervals of 2 hours and 24 hours
between. AMAP, change in mean arterial
pressure; &HR, change in heart rate; LE,
Long-Evans rats.
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indicating that the pressor response to intracerebro-
ventricular carbachol was significantly attenuated by
the vasopressin antagonist. The pressor response to
intracerebroventricular carbachol during administra-
tion of vasopressin antagonist in the LE rats was still
significantly greater than that in the DI rat. The
bradycardic response to intracerebroventricular car-
bachol was eliminated almost completely by the
vasopressin antagonist (FIi!0=8.1, p<0.0l).
The pressor effect of vasopressin at a dose of 100
ng/kg i.v. (51.7±2.8 mm Hg) was completely inhib-
ited by the treatment with the vasopressin antagonist.
Effect of Vasopressin Antidiuretic Agonist on
Cardiovascular Response to Carbachol
Twenty-four hours later, DDAVP infusion had
little effect on blood pressure (121 ±9 vs. 118±11
mm Hg, mean±SD) and heart rate (388±29 vs.
380±35 beats/min, mean±SD) in DI rats. DDAVP
decreased urinary volume significantly (298 ±25
vs. 18±4 ml/24 hr, mean±SD). Cardiovascular
responses to intracerebroventricular carbachol dur-
ing DDAVP treatment were not different from
those in the controls (blood pressure, Flr8o=O.54;
heart rate, F18O=0.36).
Modification of Cardiovascular Effect of
Carbachol by an Autonomic Blocker
Phentolamine (3 mg/kg i.v.) alone in LE rats
(70±10 mm Hg and 490±19 beats/min, mean±SD,
15 minutes after blockade) and in DI rats (66±9
mm Hg and 491 ±15 beats/min, mean±SD, 15 min-
utes after blockade) or combined with vasopressin
antagonist (5 /xg/kg i.v.) in LE rats (72±15 mm Hg
and 495±43 beats/min, mean±SD, 15 minutes after
blockade) produced extreme hypotension and tachy-
cardia (Table 1). The doses of phentolamine and
vasopressin antagonist used completely inhibited
the pressor effect of phenylephrine (10 /tg/kg i.v.,
51.0±3.5 mm Hg) and vasopressin (100 ng/kg i.v.,
48.2±2.5 mm Hg) 45 minutes after the intravenous
injection. As shown in Figure 5, the three time
courses of change in blood pressure (i.e., the
response to intracerebroventricular carbachol in
LE rats, the response to intracerebroventricular
i c.v. Carbachol
OLE rats
• LE rats + phentolamine
ALE rats + phentolamine
time control
0 1 2 3 4 5 10 20 30(m,n)
FIGURE 5. Modification of the effects of carbachol (1
/j-glkg i.c.v.) on mean arterial pressure (MAP) and heart
rate (HR) by an a-adrenergic receptor antagonist, phen-
tolamine, in Long-Evans (LE) rats. Phentolamine alone
produced extreme and prolonged hypotension and tachy-
cardia. Fifteen minutes after intravenous phentolamine,
carbachol was centrally administered. A and • demon-
strate the change in mean arterial pressure from the
blood pressure 15 minutes after phentolamine.
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TABLE 1. Basal Arterial Blood Pressure and Heart Rate in Each Experiment
Treatment Rat n Basal MBP (mm Hg) Basal HR (beats/min)
i.c.v. carbachol
i.v. carbachol
i.c.v. carbachol dose response
i.c.v. nicotine
i.c.v. physostigmine
i.v. VPVRA+i.c.v. carbachol
i.v. phentolamine+i.c.v. carbachol
i.v. phentolamine+i.v. VPVRA+i.c.v. carbachol
i.v. methylatropine+i.c.v. carbachol
i.c.v. methylatropine+i.c.v. carbachol
i.v. propranolol+i.c.v. carbachol
LE
DI
LE
DI
LE
DI
LE
DI
LE
DI
LE
LE
DI
LE
LE
LE
LE
11
22
7
7
8
8
7
7
6
6
5
6
6
5
5
5
5
109±14
118±17
101+21
123±15
109±15
119±14
110±16
113±21
103±18
110±16
lll±20
112+12
116±14
122±14
115±17
115±16
122±10
427 ±56
417+61
406±58
385±33
373±47
393 ±34
380±63
389±40
378±30
395 ±50
379±52
386±30
379±25
334+19
354±55
360±45
368±41
Values expressed are mean±SD. MBP, mean arterial blood pressure; DI
intracerebroventricular; LE, Long-Evans rats; i.v., intravenous; VPVRA
antagonist.
, Brattleboro rats; HR
, vasopressin-specific
, heart rate; i.c.v.,
vascular receptor
carbachol in LE rats with phentolamine, and the
time control obtained by phentolamine alone in LE
rats) were significantly different (F2ii68= 146.21;
/?<0.001). The Bonferroni correction for multiple
comparison revealed that the blood pressure values
between any two groups were significantly different
(p<0.05), indicating that in the LE rats intracere-
broventricular carbachol still evoked hypertension
during the treatment with intravenous phentol-
amine, although the magnitude of the pressor
response was significantly reduced. Phentolamine
also eliminated the bradycardic response to intrace-
rebroventricular carbachol in LE rats (Figure 5,
Z7! 100=7.6, p<0.0\ against intracerebroventricular
carbachol; F|ioo=O.8, p>0.3 against time control of
phentolamine alone). On the other hand, intrave-
nous phentolamine completely blocked the pressor
responses to intracerebroventricular carbachol in
the DI rats (Table 2).
Combined treatment with intravenous phentol-
amine and intravenous vasopressin antagonist in
LE rats completely inhibited the pressor and brady-
cardic responses to intracerebroventricular carba-
chol (Table 2). Methylatropine (3 /tg/kg i.c.v.)
alone in LE rats had little effect on blood pressure
(114±13mm Hg, mean±SD, 15 minutes after admin-
istration) but caused a small increase in heart rate
(370±43 beats/min, mean±SD, 15 minutes after
administration) (Table 1). Intracerebroventricular
methylatropine, however, abolished the heart rate
response almost completely and markedly attenu-
ated the blood pressure response to intracerebro-
ventricular carbachol in LE rats (Table 2). Intrace-
rebroventricular methylatropine in LE rats slightly
attenuated the depressor effect of carbachol (3 fig/
kg i.v.) (-24.6± 1.3 vs. -19.2±2.5 mm Hg, p<0.05)
30 minutes after treatment.
TABLE 2. Modification of Cardiovascular Effect of Intracerebroventricular Carbachol
Treatment
i.v. phentolamine
i.v. phentolamine+i.v. VPVRA
i.c.v. methylatropine
i.v. methylatropine
i.v. propranolol
Rat
DI
LE
LE
LE
LE
LE
MBP (mm
Before
treatment
12±1
39±2
32±5
37±4
36±2
44±6
Hg)
After
treatment
2±2*
I7±6t
2±3*
8±2*
4±4*
52±5t
HR (beats/min)
Before
treatment
-49±6
-25±9
-55±4
-58±7
-61±5
-45±3
After
treatment
1±4*
-3±4*
-2±6*
-4±3*
2±5*
-24±4*
Values expressed are mean±SEM. After treatment, 5 minutes after administration of an autonomic blocker or
vasopressin antagonist, or both. Changes in mean blood pressure (MBP) and heart rate (HR) after treatment were
obtained as a difference from the time-control experiment, i.v., intravenous; DI, Brattleboro rats; LE, Long-Evans
rats; VPVRA, vasopressin antagonist; i.c.v., intracerebroventricular.
*p<0.001; fp<0.01 compared with before treatment values.
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Methylatropine in LE rats (1 mg/kg i.v.) produced
pronounced tachycardia (492±43 beats/min,
mean±SD, 15 minutes after administration) but had
little eflFect on blood pressure (116±15 mm Hg,
mean±SD, 15 minutes after administration). It abol-
ished both the hypertensive and bradycardic responses
to intracerebroventricular carbachol (Table 2).
Propranolol in LE rats (2 mg/kg i.v.) induced
transient hypertension and long-lasting bradycar-
dia (300±14 beats/min, mean±SD, 15 minutes
after administration); the former recovered to the
initial level 15 minutes after the treatment (124± 13
mm Hg, mean±SD). Intravenous propranolol sig-
nificantly potentiated the pressor response and
attenuated the bradycardic response to intracere-
broventricular carbachol (Table 2).
Discussion
In the current study, centrally administered choli-
nomimetics elevated blood pressure and decreased
heart rate in normal conscious rats. The distinct and
different blood pressure and heart rate responses to
central cholinergic stimulation suggest a possible
differential effect of the drug on the central auto-
nomic centers governing the blood pressure and
heart rate. It is concluded that the response to
intracerebroventricular carbachol is elicited by a
central mechanism, since intravenous carbachol did
not cause hypertension and intracerebroventricular
carbachol caused bradycardia in LE but not DI rats.
Intravenous carbachol, on the other hand, pro-
duced tachycardia in both strains. Centrally admin-
istered methylatropine had little, if any, influence
on the cardiovascular response to intravenous car-
bachol, although the pressor and bradycardic effects
of intracerebroventricular carbachol were greatly
reduced.
The pressor response to intracerebroventricular
carbachol in DI rats was comparatively less than
that in normal LE rats. This difference was also
observed when physostigmine was administered
centrally. Since the effect of physostigmine is medi-
ated by the endogenous cholinergic system, the
difference of pressor response to cholinergic stimu-
lation between LE and DI rats may be physiologi-
cally significant.
It is well known that central cholinergic stimu-
lation elicits a hypertensive response in several
species of animal as well as in humans, and it is
hypothesized that the pressor eflFect is mainly medi-
ated by central muscarinic receptor mecha-
nisms.3614-16 We also have confirmed that the pres-
sor eflFect of intracerebroventricular carbachol in
rats is mediated by a central muscarinic receptor
mechanism, because methylatropine administered
centrally inhibited the pressor response to intra-
cerebroventricular carbachol. Central regions for
which the cholinergic stimulation evokes elevation
of blood pressure have been identified in several
central loci.317-19 The mechanism responsible for
the pressor response to central cholinergic stimula-
tion is controversial (see above). In the present
study the pressor response to intracerebroventricu-
lar carbachol in DI rats was completely eliminated
by an intravenous a-adrenergic receptor antagonist,
suggesting that the response is solely mediated by
an increase in sympathetic outflow. In LE rats,
however, either the a-adrenergic receptor antago-
nist or vasopressin antagonist partially attenuated
the pressor response to intracerebroventricular car-
bachol, and combined treatment with both antago-
nists completely inhibited it, indicating that in nor-
mal rats the pressor response to central cholinergic
stimulation is mediated by both an activation of the
sympathetic nervous system and an increase in
circulating vasopressin. This conclusion is also sup-
ported by the recent report by Iitake et al,6 who
demonstrated the high plasma vasopressin level
(approximately 80 pg/ml) produced by carbachol at
a dose of 250 ng i.c.v. per rat; this dose is almost
equivalent to the one used in the present study (1
fig/kg). The plasma vasopressin level reported by
these authors might be sufficient to elevate blood
pressure in conscious rats.2021
If the pressor response to intracerebroventricular
carbachol in LE rats is the product of increases in
sympathetic outflow and circulating vasopressin,
the response after the vasopressin antagonist might
be expected to be identical with that in DI rats.
However, the magnitude of the pressor response to
intracerebroventricular carbachol in LE rats after
vasopressin antagonist was still apparently greater
than that in DI rats. This may indicate that the
sympathoexcitatory response to centrally adminis-
tered carbachol in DI rats is attenuated when com-
pared with that in LE rats.
The loss of peripheral interaction between circu-
lating vasopressin and sympathetic outflow may
also explain the attenuated pressor response in Dl
rats. However, this possibility is unlikely since the
pressor response in DI rats to an a-agonist was not
different from that in normal LE rats.20
Cholinergic depressor responses, which are
believed to be mediated mainly by nicotinic
mechanisms,22-23 have also been demonstrated from
stimulation of the brainstem area. It is possible that
in DI rats the nicotinic depressor eflFect by carba-
chol is more prominent than that in LE rats, result-
ing in a smaller pressor response to the drug in the
DI rats. However, this possibility may be excluded
since the depressor effect of intracerebroventricular
nicotine in DI rats was not different from that in LE
rats.
It has been reported that centrally adminis-
tered cholinomimetics cause variable heart rate
changes.1313 In the present study, intracerebroven-
tricular carbachol induced bradycardia in normal
LE rats, but no such effect in DI rats, suggesting
that the bradycardia was mediated directly or indi-
rectly, or both, by endogenous vasopressin. Actu-
ally, in the present study, a vasopressin vascular
receptor antagonist administered peripherally inhib-
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ited the bradycardia in response to intracerebroven-
tricular carbachol almost completely. This also sug-
gests that the bradycardia was mediated by
vasopressin. This conclusion is supported by previ-
ous work in which the bradycardic response to
intravenous vasopressin was eliminated or con-
verted to tachycardia by treatment with a vaso-
pressin vascular-receptor antagonist.24-26 Vaso-
pressin may evoke bradycardia through its direct
cardiac action or its effect on the autonomic
nervous system. Modulatory effects of vasopres-
sin on the baroreceptor reflex have also been well
documented. Vasopressin augmented the barore-
ceptor reflex through both central and peripheral
mechanisms.20,27-JO \n the present study intrave-
nous methylatropine eliminated the bradycardia
almost completely, suggesting that the bradycar-
dia is mediated mainly by stimulation of the para-
sympathetic nervous system. Taken together, it is
concluded that the increase in circulating vaso-
pressin, in response to central cholinergic stimu-
lation evokes bradycardia mainly through its effect
on baroreceptor reflex-dependent or reflex-
independent autonomic neural pathways. How-
ever, in the present study it has also been con-
firmed that intravenous propranolol administered
to LE rats attenuated the bradycardia slightly but
significantly, suggesting that the bradycardia is
mediated partly by inhibition of the sympathetic
nervous system. This may indicate the differential
effect of carbachol on the central sympathetic
centers governing blood pressure and heart rate or
that the bradycardia is mediated at least in part by
inhibition of cardiac sympathetic tone, which is
reflexly induced by pressor effect of intracerebro-
ventricular carbachol.
In the present study, intravenous phentolamine
blocked the bradycardic response to centrally admin-
istered carbachol. However, the phentolamine also
caused a pronounced reduction in arterial pressure,
which in turn probably caused a major release of
vasopressin and a large increase in the plasma
vasopressin concentration. In this circumstance it is
uncertain whether the subsequent administration of
carbachol would have any further effect on vaso-
pressin release or heart rate.
It is believed that methylatropine administered
peripherally does not affect the central cholinergic
system.31 However, in the present study methyl-
atropine in a 1 mg/kg i.v. dose abolished the cardio-
vascular response to intracerebroventricular carba-
chol, suggesting that methylatropine administered
peripherally may block the central muscarinic recep-
tor to release vasopressin. Therefore, in the present
study it was difficult to estimate qualitatively or
quantitatively the role of peripheral parasympa-
thetic nervous system for the cardiovascular
response to centrally administered carbachol. Thus,
the possibility remains that elevated circulating
vasopressin acts directly on the heart to evoke
bradycardia.
As a remaining explanation for the differential
cardiovascular responses to intracerebroventricular
carbachol seen in LE and DI rats, differential vol-
ume and level of hydration between the two strains
may be postulated. However, this possibility is
unlikely since DDAVP did not modulate the cardio-
vascular responses to intracerebroventricular car-
bachol, whereas DDAVP restored the urinary pro-
duction in the DI rats to within the range in the LE
rats.
In summary, it is concluded that central cholinergic
muscarinic receptor mechanism contributes to cardio-
vascular regulation through the effect on vasopressin
release as well as on the autonomic nervous system.
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